Peptides Show Promise Against Muscle Wasting: A Comprehensive Research Overview

Skeletal muscle wasting, characterized by progressive loss of muscle mass and strength, is a debilitating condition associated with numerous diseases like cancer cachexia, sarcopenia (age-related muscle loss), and chronic kidney disease. This loss significantly impairs quality of life and increases mortality. While various interventions exist, their efficacy is often limited. Peptides, due to their high specificity and diverse biological activities, are emerging as potential therapeutic agents. However, a comprehensive overview of the current landscape of peptide research in skeletal muscle wasting was lacking.

The review identified over 60 distinct peptides that have been investigated for their potential in combating skeletal muscle wasting, categorized into several key groups based on their proposed mechanisms. Approximately 70% of the included studies were preclinical, with 45% focusing on in vivo animal models and 25% on in vitro cell culture experiments. Only 10% of the identified research involved human clinical trials, indicating a significant gap in translational research. The most frequently studied peptides targeted pathways related to growth hormone secretion, myostatin inhibition, and anti-inflammatory effects, showing promising results in preclinical settings. For instance, peptides influencing the GH/IGF-1 axis were prominent, with over 30 studies exploring their anabolic effects, while 20 studies focused on myostatin inhibitors.